AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics

Latest Clinical Considerations for Timing of a Systemic Treatment in Plaque Psoriasis Patients with Limited Skin Disease

This content is sponsored by Amgen and was developed in conjunction with Linda Stein Gold, MD, April Armstrong, MD, both of whom were compensated by Amgen for their participation.

Music Legend Art Garfunkel Shares His Journey with Psoriasis for the First Time in Collaboration with Sun Pharma

PRINCETON, N.J., April 8, 2025 / – In a powerful new partnership with Sun Pharmaceutical Industries Inc., iconic singer and 8-time Grammy Award winner Art Garfunkel is speaking publicly for the first time about his experience living with moderate-to-severe plaque psoriasis. As part of Sun Pharma’s “I LUV YA for The Long Haul” campaign, Garfunkel shares his story of resilience and the role ILUMYA® (tildrakizumab-asmn) played in his treatment jour…

Morphosys' antibody still shining - for J&J - European Biotechnology Magazine

The case of the psoriasis antiinflammation antibody guselkumab is a story of deals and cooperation and selling and buying royalties to fuel other innovation paths. J&J is right in the middle of the game and has now full ownership while expanding the indications further. The post Morphosys’ antibody still shining – for J&J appeared first on European Biotechnology Magazine.

Evaluating Biologic Treatment as Monotherapy for Atopic Dermatitis

Panelists discuss how pivotal clinical trials for atopic dermatitis biologics demonstrate both rapid and durable efficacy as monotherapy, with 3 agents—dupilumab (SOLO 1/2), lebrikizumab (ADvocate 1/2), and tralokinumab (ECZTRA 1/2)—achieving significantly higher rates of clear/almost clear skin (IGA 0/1) at week 16 vs placebo; early itch improvement by week 2; and, importantly, sustained response among initial responders at week 52, with mainte…

AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.